Text of AZ SB 1702 (2023)
Gender transition; prohibitions; hormone therapies
Legislative text is a public record. Where LegiScan supplied it, the CC BY 4.0 credit applies.
Source: LegiScan. Bill data and text from LegiScan (legiscan.com), licensed CC BY 4.0 and used in modified form. LegiScan does not endorse the Trans Data Initiative. License: CC BY 4.0(opens another site). Source page(opens another site)
As introduced
5,299 characters
REFERENCE TITLE: gender transition;
prohibitions; hormone therapies
State of
Arizona
Senate
Fifty-sixth
Legislature
First Regular
Session
2023
SB 1702
Introduced by
Senator Wadsack: Representatives Jones, McGarr
An Act
amending
section 32-3230, Arizona Revised Statutes; relating to health
professionals.
(TEXT OF BILL BEGINS ON NEXT PAGE)
Be it enacted by the Legislature of the State of Arizona:
Section 1. Section 32-3230, Arizona Revised
Statutes, is amended to read:
START_STATUTE32-3230. Prohibition of permanent gender reassignment surgery for minors;
prohibition on referring for or providing hormone therapy for minors;
definitions
A. A physician may not provide irreversible PERMANENT gender reassignment surgery to any individual who is
under eighteen years of age. A health professional may not make
a referral for or provide cross-sex hormones or puberty-blocking
drugs to any individual who is under eighteen years of age.
B. A physician may provide any of the following to
an individual who is under eighteen years of age:
1. Services to an individual born with a medically verifiable
disorder of sex development, including an individual with external biological
sex characteristics that are irresolvably ambiguous, such as being born with
forty-six XX chromosomes with virilization or forty-six
XY chromosomes with undervirilization or having both ovarian and
testicular tissue.
2. Services provided when a
physician has otherwise diagnosed a disorder of sexual development and has
determined through genetic or biochemical testing that the individual does not
have normal sex chromosome structure, sex steroid hormone production or sex
steroid hormone action.
3. The treatment of any infection, injury, disease
or disorder that has been caused by or exacerbated by the performance of gender
transition procedures, whether or not the gender transition procedure was
performed in accordance with state and federal law.
4. Any procedure undertaken because the individual
suffers from a physical disorder, physical injury or physical illness that
would, as certified by a physician, place the individual in imminent danger of
death or impairment of major bodily function unless surgery is performed.
C. For the purposes of this section:
1. "Biological sex" means the biological
indication of male and female in the context of reproductive potential or
capacity, such as sex chromosomes, naturally occurring sex hormones, gonads and
nonambiguous internal and external genitalia present at birth, without regard
to an individual's psychological, chosen or subjective experience of gender.
2. "Cross-sex
hormones" means either of the following:
(a) Testosterone
or other androgens given to biological females in amounts that are larger or
more potent than would normally occur naturally in healthy biological sex
females.
(b) Estrogen
given to biological males in amounts that are larger or more potent than would
normally occur naturally in healthy biological sex males.
2. 3. "Gender"
means the psychological, behavioral, social and cultural aspects of being male
or female.
3. 4. "Gender
transition" means the process in which a person goes from identifying with
and living as a gender that corresponds to the person's biological sex to
identifying with and living as a gender different from the person's biological
sex and may involve social, legal or physical changes.
4. 5. "Irreversible PERMANENT gender reassignment
surgery" means a medical procedure performed for the purpose of assisting
an individual with a gender transition, including any of the following:
(a) Penectomy, orchiectomy, vaginoplasty,
clitoroplasty or vulvoplasty for biologically male patients or hysterectomy or
ovariectomy for biologically female patients.
(b) Metoidioplasty, phalloplasty, vaginectomy,
scrotoplasty or implantation of erection or testicular prostheses for biologically
female patients.
(c) Augmentation mammoplasty for biologically male
patients and subcutaneous mastectomy for female patients.
5. 6. "Physician"
means a person who is licensed pursuant to chapter 13 or 17 of this title.
7. "Puberty-blocking drugs"
means either of the following when used to delay or suppress pubertal
development in children for the purpose of assisting an individual with a
gender transition:
(a) Gonadotropin-releasing
hormone analogues or other synthetic drugs used in biological sex males to stop
luteinizing hormone secretion and testosterone secretion.
(b) Synthetic
drugs used in biological sex females to stop the production of estrogens and
progesterone. END_STATUTE
Sec. 2. Effective date;
purpose
A. This act is effective from and after March 31,
2024.
B. The effective date of this act is delayed so that
minors in this state who are currently using puberty-blocking drugs or
cross-sex hormones have time for appropriate medication tapering and
discontinuation under the care of the minor's physician or other health
professional.